The contribution of calpains in the down-regulation of Mdm2 and p53 proteolysis in reconstructed human epidermis in response to solar irradiation

Photochemistry and Photobiology

Volumn 81, Issue 4, 2005, Pages 975-983

  Gélis, Christelle ^a,b   Mavon, Alain ^b   Vicendo, Patricia ^a,c  

^a UMR 5623 CNRS UPS)   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MURINAE;

EID: 24644457026     PISSN: 00318655     EISSN: None     Source Type: Journal    
DOI: 10.1562/2004-08-05-RA-262R.1     Document Type: Article

References (65)

1. Harris, C. C. (1993) p53: at the crossroad of molecular carcinogenesis and risk assessment. Science 262, 1980-1981.
2. Hofseth, L. J, S. P. Hussain and C. C. Harris (2004) p53: 25 years after its discovery. Trends Pharmacol. Sci. 25, 177-181.
3. Levine, A. J. (1997) The p53 tumor suppressor gene. Nature 351, 453-456.
4. Levine, A. J. (1997) p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
5. Maltzam, W. and L. Czyzyk (1984) UV irradiation stimulates levels of p53 cellular tumor antigen in transformed mouse cells. Mol. Cell. Biol. 4, 1689-1694.
6. Noda, A., Y. Toma-Aiba and Y. Fujiwara (2000) A unique, short sequence determines p53 gene basal and UV-inducible expression in normal human cells. Oncogene 19, 21-31.
7. Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein and R. W. Craig (1991) Participation of p53 protein in cellular response to DNA damage. Cancer Res. 51, 6304-6311.
8. Ziegler, A., A. S. Jonason, D. J. Leffell, J. A. Simon, H. W. Sharma, J. Kimmelman, L. Remington, T. Jacks and D. E. Brash (1994) Sunburn and p53 in the onset of skin cancer. Nature 372, 773-776.
9. Geyer, R. K., H. Nagasawa, J. B. Little and C. G. Maki (2000) Role and regulation of p53 during an ultraviolet radiation-induced G1 cell cycle arrest. Cell Growth Differ. 11, 149-156.
10. Hwang, B. J., J. M. Ford, P. C. Hanawalt and G. Chu (1999) Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc. Natl. Acad. Sci. USA 96, 424-428.
11. Maltzman, W. and L. Czyzyk (1984) UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4, 1689-1694.
12. Oliner, J. D., J. A. Pietenpol, S. Thiallingam, J. Gyuris, K. W. Kinzler and B. Vogelstein (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857-860.
13. Kubbutat, M. H., S. N. Jones and K. H. Vousden (1997) Regulation of p53 stability by Mdm2. Nature 387, 299-303.
14. Haupt, Y., R. Maya, A. Kazaz and M. Oren (1997) Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
15. Giaccia, A. J. and M. B. Kastan (1998) The complexity of p53 modulation emerging patterns from divergent signals. Genes Dev. 12, 2973-2983.
16. Prives, C. (1998) How loops, β sheets and α helices help us to understand p53. Cell 95, 5-8.
17. Shieh, S. Y., M. Ikeda, Y. Taya and C. Prives (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334.
18. Molinari, M. and J. Milner (1995) p53 in complex with DNA is resistant to ubiquitin dependent proteolysis in the presence of HPV-16 E6. Oncogene 10, 1849-1854.
19. Myung, J., K. B. Kim and C. M. Crews (2001) The ubiquitin-proteasome pathway and proteasome inhibitors. Med. Res. Rev. 21, 245-73.
20. Rolfe, M., M. I. Chiu and M. Pagano (1997) The ubiquitin-mediated proteolytic pathway as a therapeutic area. J. Mol. Med. 75, 5-17.
21. Weissman, A.M. (1997) Regulating protein degradation by ubiquitination. Immunol. Today 18, 189-198.
22. Giaccia, A. J. and M. B. Kastan (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12, 2973-2983.
23. Buschmann, T., S. Y. Fuchs, C. G. Lee, Z. Q. Pan and Z. Ronai (2000) SUMO-1 modification of Mdm2 prevents its self ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell 101, 753-762.
24. Kubbutat, M. H. and K. H. Vousden (1997) Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell Biol. 17, 460-468.
25. Saido, T. C., H. Sorimachi and K. Suzuki (1994) Calpain: new perspectives in molecular diversity and physiological pathological involvement. FASEB J. 8, 814-822.
26. Croall, D. E. and G. N. Demartino (1991) Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol. Rev. 71, 813-847.
27. Gonen, H., D. Shkedy, S. Barnoy, N. S. Kosower and A. Ciechanover (1997) On the involvement of calpains in the degradation of the tumor suppressor protein p53. FEBS Lett. 406, 17-22.
28. Fox, J. E. B. and T. C. Saido (1999) Calpain in signal transduction. In Calpain: Pharmacology and Toxicology of Calcium-Dependent Protease (Edited by K. K. W. Wang and P. W. Yen), pp. 103-126. Taylor and Francis, Philadelphia.
29. Pfaff, M., X. Du and M. H. Ginsberg (1999) Calpain cleavage of integrin β cytoplasmic domains. FEBS Lett. 460, 17-22.
30. Schoenwaelder S. M., Y. Yuan, P. Cooray, H. H. Salem and S. P. Jackson (1997) Calpain cleavage of focal adhesion proteins regulates the cytoskeletal attachment of integrin αIIbβ3 (platelet glycoprotein IIb/IIIa) and the cellular retraction of fibrin clots. J. Biol. Chem. 272, 1694-1702.
31. Fox, J. E. (1999) On the role of calpain and Rho protein in regulating integrin-induced signalling. Thromb. Haemost. 82, 385-391.
32. Glading, A., P. Chang, D. A. Lauffenburger and A. Wells (2000) Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signalling pathway. J. Biol. Chem. 275, 2390-2398.
33. Glading, A., F. Überall, S. M. Keyse, D. A. Lauffenburger and A. Wells (2001) Membrane proximal ERK signalling is required for m-calpain activation downstream of epidermal growth factor receptor signalling. J. Biol. Chem. 276, 23341-23348.
34. Kishimoto, A., K. Mikawa, K. Hashimoto, I. Yasuka, S. Tanaka, M. Tominaga, T. Kuroda and Y. Nishimura (1989) Limited proteolysis of protein kinase C subspecies by calcium-dependent neutral protease (calpain). J. Biol. Chem. 264, 4088-4092.
35. Frangioni, J. V., A. Oda, M. Smith, E. W. Salzman and B. G. Neel (1993) Calpain-catalyzed cleavage and subcellular relocation of protein phosphotyrosine phosphatase 1B (PTP-1B) in human platelets. EMBO J. 12, 4843-4856.
36. Banno Y., S. Nakashima, T. Hachiya and Y. Nozawa (1995) Endogenous cleavage of phospholipase C-beta 3 by agonist-induced activation of calpain in human platelets. J. Biol. Chem. 270, 4318-4324.
37. Goll, D. E., V. F. Thompson, H. Li, W. Wei and J. Cong (2003) The calpain system. Physiol. Rev. 83, 731-801.
38. Garach-Jehoshua, O., A. Ravid, U. A. Liberman, J. Reichratch, T. Glasers and R. Koren (1998) Upregulation of the calcium-dependent protease, calpain, during keratinocyte differentiation. Br. J. Dermatol. 139, 950-957.
39. Saido, T. C., M. Shibata, T. Takenawa, H. Murofushi and S. Suzuki (1992) Positive regulation of mu-calpain action by polyphosphoinositides. J. Biol. Chem. 267, 24585-24590.
40. Piechaczyk, M. (2000) Proteolysis of p53 protein by ubiquitous calpains. Methods Mol. Biol. 144, 297-307.
41. Atencio, I. A., M. Ramachandra, P. Shabram and G. W. Demers (2000) Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines. Cell Growth Diff. 11, 247-253.
42. Bernard, F. X., N. Pedretti, M. Rosdy and A. Deguercy (2002) Comparison of gene expression profiles in human keratinocytes mono-layer cultures, reconstructed epidermis and normal human skin; transcriptional effects of retinoid treatments in reconstructed human epidermis. Exp. Dermatol. 11, 59-74.
43. Gazel, A., P. Ramphal, M. Rosdy, B. De Wever, C. Tornier, N. Hosein, B. Lee, M. Tomic-Canic and M. Blumenberg (2003) Transcriptional profiling of epidermal keratinocytes: comparison of genes expressed in skin, cultured keratinocytes, and reconstructed human epidermis, using large DNA microarrays. J. Invest. Dermatol. 121, 1459-1468.
44. Bernard, F. X., C. Barrault, A. Deguercy, B. De Wever and M. Rosdy (2000) Development of a highly sensitive in vitro phototoxicity assay using the SkinEthic reconstructed human epidermis. Cell Biol. Toxicol. 16, 391-400.
45. Rosdy, M. and L. C. Clauss (1990) Terminal epidermal differentiation of human keratinocytes grown in chemically defined medium on inert filter substrates at the air-liquid interface. J. Invest. Dermatol. 95, 409-414.
46. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63.
47. Smith, P. K., R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson and D. C. Klenk (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85.
48. Picksley, S. M., B. Vojtesek, A. Spark and D. P. Lane (1994) Immunochemical analysis of the interaction of p53 with MDM2 - fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogenes 9, 2523-2529.
49. Ashcroft, M. and K. H. Vousden (1999) Regulation of p53 stability. Oncogene 18, 7637-7643.
50. Pathak, M. A. (1996) Sunscreens: progress and perspectives on photoprotection of human skin against UVB and UVA radiation. Dermatology 23, 783-800.
51. Kaidbey, K. H. (1990) The protective potential of the new superpotent sunscreen. J. Am. Acad. Dermatol. 22, 449-452.
52. Liu, M., K. Dhanwada, D. Birt, S. Hecht and J. Pelling (1994) Increase in p53 protein half-life in mouse keratinocytes following UV-B irradiation. Carcinogenesis 15, 1089-1092.
53. Courtois S., C. Woodworth, H. Degreef and M. Garmyn (1997) Early ultraviolet B-induced G1 arrest and suppression of the malignant phenotype by wild-type p53 in human squamous cell carcinoma cells. Exp. Cell Res. 233, 135-144.
54. Hall, P. A., P. H. McKee, H. Menage, R. Dover and D. P. Lane (1993) High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8, 203-207.
55. Pariat, M., S. Carillo, M. Molinari, C. Salvat, L. Debüssche, L. Bracco, J. Milner and M. Piechaczyk (1997) Proteolysis by calpains: a possible contribution to degradation of p53. Mol. Cell. Biol. 17, 2806-2815.
56. Burden, A. D., G. I. Stables, I. Campbell, W. Thomson and R. M. Mackie (1996) Mdm2 is not induced by p 53 in human keratinocytes in vivo. J. Cutan. Pathol. 23, 25-29.
57. Unger, T., T. Juven-Gershon, E. Moallem, M. Berger, R. Vogt Sionov, G. Lozano, M. Oren and Y. Haupt (1999) The ubiquitin-mediated proteolytic pathway as a therapeutic area. EMBO J. 18: 1805-1814.
58. Chehab, N. H., A. Malikray, E. S. Stavridi, and T. D. Halaronetis (1999) Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc. Natl. Acad. Sci. USA 96, 14973-14977.
59. Maki, G. C. and P. M. Howley (1997) Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell. Biol. 17, 355-363.
60. Maki, G. C. (1999) Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J. Biol. Chem. 274, 16531-16535.
61. Inoue, T., R. K. Geyer, Z. K. Yu and C. G. Maki (2001) Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents. FEBS Lett. 490, 196-201.
62. Bartus, R. T., P. J. Eliott, N. J. Hayward, R. L. Dean, S. Harberson, J. A. Straub, Z. Li and J. C. Powers (1995) Calpain as a novel target for treating acute neurodegenerative disorders. Neurol. Res. 17, 249-258.
63. Robinson, A. (1996) Inhibiting calpain, rescuing cells. C.M.A.J. 154, 193-195.
64. Wang, K. K. and P. W. Yuen (1994) Calpain inhibition: an overview of its therapeutic potential. Trends Pharmacol. Sci. 15, 412-419.
65. Liu, Z. Q., M. Kunimatsu, J. P. Yang, Y. Ozaki, M. Sasaki and T. Okamoto (1996) Proteolytic processing of nuclear factor kB by calpain in vitro. FEBS Lett. 385, 109-113.